Why the study?
Does transcatheter tricuspid valve intervention (TTVI) improve survival compared to medical therapy alone, and are there sex-related differences in outcomes for high-risk patients with tricuspid regurgitation?
Does transcatheter tricuspid valve intervention (TTVI) improve survival compared to medical therapy alone, and are there sex-related differences in outcomes for high-risk patients with tricuspid regurgitation?
TTVI provides a survival benefit over medical therapy alone in high-risk patients with tricuspid regurgitation, with similar short-term efficacy and clinical outcomes observed in both men and women.
No sex differences in TTVI outcomes to 1 year; leaves open randomized confirmation of survival benefit over medical therapy.
After TTVI in high-risk patients, there were no sex-related differences in terms of survival, HF hospitalization, functional status, and TR reduction up to 1 year. The IPTW analysis shows a survival benefit of TTVI over medical therapy alone in both women and men.
No takes yet. Share an insight, caveat, or question.
Scotti et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: